Womenwith cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapymay be eligible to participate in this trial. The treatment, which will consist of two treatment arms, will assess the efficacy and safety of AGEN2034 administered with placebo or with AGEN1884.AGEN2034 and AGEN1884 are antibodies that activate the immune system to destroy cancer cells by blocking two negative regulators of immune activation, PD-1 (programmed cell death protein 1)and CTLA-4 (cytotoxic T-lymphocyte antigen-4), respectively.
Participants must meet the following criteria be eligible for the trial:
If you've answered yes to all of the above questions, please
Email:obgynresearch@mednet.ucla.edu or Call: (310) 794-9652.
Once in the study, participants will be randomized (like drawing numbers from a hat) to one of two treatment arms.Patients in Treatment Arm 1 will receive monotherapy of AGEN2034 with placebo. Patients in Treatment Arm 2 will receive AGEN2034 with AGEN1884 as combination therapy.Physicians, patients, and research personnel will not know whether patient has received AGEN2034 + placebo (Treatment Arm 1) or AGEN2034 + AGEN1884 (Treatment Arm 2).Treatment will last a maximum of 24 months or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study or withdrawal from the trial occurs.
All participants enrolled in the study will undergo the following testing:
UCLA Protocol ID: IRB# 19-000800
Please call (310) 794-9652 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.
